4D Molecular Therapeutics 배당금 및 환매

배당금 기준 확인 0/6

4D Molecular Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-98.5%

환매 수익률

총 주주 수익률	-98.5%
미래 배당 수익률	0%
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Nov 24

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 FDMT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: FDMT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

4D Molecular Therapeutics 시장 대비 배당 수익률

FDMT 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (FDMT)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.2%
업계 평균 (Biotechs)	2.3%
애널리스트 예측 (FDMT) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 FDMT 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 FDMT 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 FDMT 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: FDMT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

4D Molecular Therapeutics 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Price target decreased by 8.7% to US$45.64

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

New major risk - Revenue and earnings growth

New major risk - Share price stability

4D Molecular Therapeutics Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4Front Phase 3 Program At 4D-150 Wet AMD Development Day

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

4D Molecular Therapeutics, Inc. Announces Management Changes

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

4D Molecular Therapeutics, Inc. Announces Initial Interim 24-Week Data from the Population Extension Cohort of Its Phase 2 Clinical Trial

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis At 47Th European Cystic Fibrosis Conference

First quarter 2024 earnings released: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc., Annual General Meeting, May 21, 2024

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 9.3% to US$54.75

4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Consensus revenue estimates decrease by 33%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Chief Medical Officer exercised options and sold US$354k worth of stock

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $299.999626 million.

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

4D Molecular Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

New major risk - Share price stability

Price target increased by 9.6% to US$37.00

4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

Co-Founder notifies of intention to sell stock

Insufficient new directors

Consensus revenue estimates increase by 96%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis At 2023 NACFC

4D Molecular Therapeutics, Inc. Announced Alignment with the U.S. Food and Drug Administration on A Plan to Lift the Clinical Hold on the Phase 1/2 Inglaxa Clinical Trial in the United States

4D Molecular Therapeutics, Inc. Announces Executive Changes

Price target decreased by 14% to US$33.50

4D Molecular Therapeutics, Inc. Announces First Patient Enrolled in 4D-150 Phase 2 Spectra Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in Prism Clinical Trial in Wet AMD

Consensus revenue estimates increase by 41%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023

Consensus revenue estimates increase by 163%

4D Molecular Therapeutics Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at ECFS 46th Annual Meeting

4Dmt to Present Interim Data from 4D-710 Phase 1/2 Aerow Clinical Trial for Cystic Fibrosis Lung Disease At the European Cystic Fibrosis Society (Ecfs) 46Th Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Price target increased by 8.3% to US$41.17

Full year 2022 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

Price target increased by 8.1% to US$38.00

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$85k worth of stock

Price target increased to US$23.80

High number of new directors

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from On-Going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released November 14, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease At NACFC 2022

High number of new directors

High number of new directors